Warning to fat jabs users as patients start pilling on pounds after treatment stops, research shows
FAT IS BACK Warning to fat jabs users as patients start pilling on pounds after treatment stops, research shows
PEOPLE on weight-loss jabs start piling the flab back on just two months after they stop taking them, research shows.
The drugs work well for those who have failed other methods or are very large.
However, the hunger signals they block can start up again once the treatment ends.
A review of 11 studies covering more than 2,000 slimmers found they kept the weight off for at least four weeks after stopping, but started putting it back on by the eight-week mark.
And their weight gain tended to continue for five months before it stabilised.
Patients who took popular fat jab Mounjaro regained almost half the weight they had lost while on the drug.
Study author Dr Xiaoling Cai, from Peking University People's Hospital in China, said: 'Weight regain is common, so it is necessary to establish long-term anti-obesity treatment.'
Katherine Jenner, director of Britain's Obesity Health Alliance, said: 'This underlines why we can't medicate ourselves out of the obesity crisis.
"Without tackling the root causes, people are left swimming against the tide.'
A separate study at Oxford University suggested many fat jab patients regain all the weight they lose within two years of stopping medication.
NHS prescriptions for jabs like Wegovy and Mounjaro hit 2.7million in England last year — and more people are buying privately, potentially missing out on diet and lifestyle advice.
I've lost nearly 6 stone in 9 months on fat jabs - trolls call me 'lazy' & say it's the 'easy way out' but I don't care
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
6 minutes ago
- The Independent
Women with advanced cancer get fresh hope as new treatment approved on NHS
Thousands of women battling an advanced form of womb cancer have been offered renewed hope after a new treatment was approved for widespread use on the NHS. Currently, just 15 per cent of women diagnosed with advanced (stage four) endometrial cancer – which typically originates in the lining of the womb – survive for five years. The treatment, known as pembrolizumab, has been shown to slow cancer growth and significantly improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that approximately 2,100 women across England will benefit from the therapy each year. Nice hailed its approval as a "major step forward" in the treatment of the cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel. It can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26 per cent compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'
Wales Online
2 hours ago
- Wales Online
New fast-tracked treatment for advanced cancer is 'major step forward'
New fast-tracked treatment for advanced cancer is 'major step forward' Just 15% of patients currently live for five years once diagnosed Women with an advanced form of womb cancer have been given fresh hope (Image: Jeff Moore/PA Wire) Women with an advanced form of womb cancer have been given fresh hope after a new treatment was given the green light for widespread NHS use. Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Article continues below Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. It is great news that this new treatment has been approved. It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'
BBC News
2 hours ago
- BBC News
Planned closure of local Healthwatch criticised
Concern has been raised about plans to scrap local Healthwatch organisations and bring feedback and engagement acts as the independent patient voice, feeding back experiences, complaints and local needs to NHS trusts and primary care providers, including integrated care boards (ICB).But the government has announced plans to scrap all 153 of the local boards with Health Secretary Wes Streeting saying the NHS needs "more doers and fewer checkers".One patient who has used Healthwatch on the Isle of Wight said bringing the service in-house would be allowing the ICB to "mark their own homework". Ieuan Jehu turned to Healthwatch Isle of Wight last year when the final dentist practice in Freshwater providing NHS services announced it was to close. He said "Healthwatch were invalable in helping to save the service and find a new operator to take the surgery over. My experience with them was excellent, they listened and kept me informed of what was happening."Mr Jehu said he would welcome a stronger organisation representing patients as sometimes Healthwatch "lacked teeth", but said ICBs themselves would not be able to advocate for patients and hold their own management to account. Healthwatch chairs across the South have said the plan will undermine the independence and effectiveness of the public voice in health and social Veronica Barry, Executive Director of Healthwatch Oxfordshire said they were proud of their work engaging with people and communities across the county, including those who don't always give their views."The voice outside the system for patients to advocate or listen on their behalf was really important. Once you bring that function within a system, within health and care it, it can be very difficult for them to really engage and hear." Siobhain McCurruch, Healthwatch Area Director Hampshire and Portsmouth added "it's hard to understand the reasoning behind dismantling something that will eventually need to be rebuilt," adding "we urge the Government to urgently rethink this very important decision that will have an adverse impact on the local, independent voice".In the statement, the Department for Health and Social care (DHSC) acknowledged the successes of Healthwatch but said "these changes will make things clearer for patients and give them a stronger voice. Through our 10 Year Health Plan we will bring patient care into the 21st century, using tech and AI to make checks more rigorous and efficient and ensure we never turn a blind eye to failure."The timeframe for the closure of the Healthwatch network is still unclear and is subject to further legislation by the now, the organisations say they will continue to fufill their role and are encouraging patients to contact them about their health and social care experiences. You can follow BBC Hampshire & Isle of Wight on Facebook, X (Twitter), or Instagram.
